[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR084102A1 - Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos - Google Patents

Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos

Info

Publication number
AR084102A1
AR084102A1 ARP110104773A ARP110104773A AR084102A1 AR 084102 A1 AR084102 A1 AR 084102A1 AR P110104773 A ARP110104773 A AR P110104773A AR P110104773 A ARP110104773 A AR P110104773A AR 084102 A1 AR084102 A1 AR 084102A1
Authority
AR
Argentina
Prior art keywords
prepare
compressed
dimethyl
trioxo
iodo
Prior art date
Application number
ARP110104773A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR084102A1 publication Critical patent/AR084102A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Comprimido farmacéutico que comprende: a) una cantidad de fármaco, que es el solvato de dimetilsulfóxido de la N{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, seleccionada entre 0,5635 mg y 2,254 mg; en el que el comprimido contiene de 25% a 89% en peso de uno o más excipientes, en el que los excipientes carecen sustancialmente de agua y la cantidad de fármaco no solvatado no supera 20%. Los excipientes se seleccionan entre: celulosa microcristalina, celulosa en polvo, almidón pregelatinizado, almidón, lactosa, fosfato dicálcico, lactitol, manitol, sorbitol y maltodextrina. Su uso para preparar un medicamento útil para tratar el cáncer en un ser humano. Procedimiento para preparar dichos comprimidos.
ARP110104773A 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos AR084102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
AR084102A1 true AR084102A1 (es) 2013-04-24

Family

ID=46314827

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104773A AR084102A1 (es) 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
ARP210101433A AR122185A2 (es) 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101433A AR122185A2 (es) 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Country Status (37)

Country Link
US (5) US8580304B2 (es)
EP (4) EP3808343A1 (es)
JP (2) JP6126014B2 (es)
KR (1) KR101911109B1 (es)
CN (1) CN103998041B (es)
AR (2) AR084102A1 (es)
AU (1) AU2011349422B2 (es)
BR (1) BR112013015602B1 (es)
CA (1) CA2822701C (es)
CL (1) CL2013001779A1 (es)
CR (1) CR20130352A (es)
CY (1) CY1123376T1 (es)
DK (3) DK4159205T3 (es)
DO (1) DOP2013000138A (es)
EA (1) EA025198B1 (es)
ES (3) ES2985024T3 (es)
FI (2) FI4159205T3 (es)
HR (3) HRP20240564T1 (es)
HU (3) HUE066526T2 (es)
IL (1) IL226855A (es)
JO (1) JO3594B1 (es)
LT (3) LT2654736T (es)
MA (1) MA34883B1 (es)
MX (1) MX2013007073A (es)
MY (1) MY170501A (es)
NZ (1) NZ612157A (es)
PE (1) PE20140040A1 (es)
PL (3) PL2654736T3 (es)
PT (3) PT4159205T (es)
RS (2) RS65497B1 (es)
SG (1) SG191054A1 (es)
SI (3) SI2654736T1 (es)
TW (1) TWI505828B (es)
UA (1) UA113158C2 (es)
UY (1) UY33818A (es)
WO (1) WO2012088033A2 (es)
ZA (1) ZA201304189B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110251512A (zh) 2012-08-17 2019-09-20 霍夫曼-拉罗奇有限公司 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法
IL300664A (en) * 2012-11-30 2023-04-01 Novartis Ag Innovative pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
MX2019001579A (es) 2016-08-10 2019-06-20 Hoffmann La Roche Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
TW201818936A (zh) * 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
PT3618875T (pt) 2017-05-02 2023-08-07 Novartis Ag Terapia de combinação que compreende um inibidor de raf e trametinib
JP2022540253A (ja) 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ, インコーポレイテッド T型カルシウムチャネル調節因子の製剤およびその使用方法
US20220354951A1 (en) 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PT1761528E (pt) 2004-06-11 2008-04-15 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
US20080145433A1 (en) * 2006-11-09 2008-06-19 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
JP5479337B2 (ja) * 2007-07-30 2014-04-23 アルディア バイオサイエンス,インク. Mek阻害剤およびrafキナーゼ阻害剤の組み合わせ、ならびにその使用
RU2470641C2 (ru) * 2007-09-25 2012-12-27 Тева Фармасьютикал Индастриес Лтд. Стабильные составы иматиниба
US8822482B2 (en) 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
US20120283278A1 (en) 2009-09-23 2012-11-08 Melissa Dumble Combination
KR20120099219A (ko) 2009-09-23 2012-09-07 글락소스미스클라인 엘엘씨 조합물
WO2011038380A2 (en) 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
PL3560498T3 (pl) 2009-10-16 2022-12-12 Novartis Ag Kombinacja zawierająca inhibitor mek i inhibitor b-raf
SG10201407558TA (en) 2009-11-17 2015-01-29 Glaxosmithkline Llc Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
EA201390913A1 (ru) 2014-04-30
CA2822701C (en) 2018-10-23
JO3594B1 (ar) 2020-07-05
HRP20240564T1 (hr) 2024-09-27
HUE066526T2 (hu) 2024-08-28
US20140154316A1 (en) 2014-06-05
PT4159204T (pt) 2024-05-07
HUE066525T2 (hu) 2024-08-28
ES2985024T3 (es) 2024-11-04
UA113158C2 (xx) 2016-12-26
UY33818A (es) 2012-07-31
WO2012088033A2 (en) 2012-06-28
HRP20201409T1 (hr) 2020-11-27
HRP20240563T1 (hr) 2024-08-16
US20120183613A1 (en) 2012-07-19
RS65496B1 (sr) 2024-06-28
ES2982775T3 (es) 2024-10-17
BR112013015602B1 (pt) 2022-03-03
US9399021B2 (en) 2016-07-26
SI4159205T1 (sl) 2024-06-28
JP2017137299A (ja) 2017-08-10
US9271941B2 (en) 2016-03-01
EA025198B1 (ru) 2016-11-30
US9155706B2 (en) 2015-10-13
ES2820536T3 (es) 2021-04-21
MY170501A (en) 2019-08-08
PT4159205T (pt) 2024-05-08
PL4159205T3 (pl) 2024-06-24
CR20130352A (es) 2013-12-18
CN103998041B (zh) 2016-08-17
US8580304B2 (en) 2013-11-12
DK2654736T3 (da) 2020-09-14
SG191054A1 (en) 2013-08-30
US20130266649A1 (en) 2013-10-10
HUE050788T2 (hu) 2021-01-28
TW201249441A (en) 2012-12-16
WO2012088033A3 (en) 2014-03-13
TWI505828B (zh) 2015-11-01
US20140037726A1 (en) 2014-02-06
LT4159204T (lt) 2024-05-10
KR101911109B1 (ko) 2018-10-23
PL4159204T3 (pl) 2024-07-01
EP4159205A1 (en) 2023-04-05
EP4159205B1 (en) 2024-02-14
PE20140040A1 (es) 2014-02-26
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
FI4159204T3 (fi) 2024-04-22
KR20130130028A (ko) 2013-11-29
CN103998041A (zh) 2014-08-20
LT2654736T (lt) 2020-09-25
CA2822701A1 (en) 2012-06-28
EP2654736A4 (en) 2015-04-22
EP3808343A1 (en) 2021-04-21
EP4159204A1 (en) 2023-04-05
DK4159205T3 (da) 2024-05-13
BR112013015602A2 (pt) 2017-02-21
IL226855A (en) 2017-04-30
PT2654736T (pt) 2020-09-24
EP4159204B1 (en) 2024-02-14
EP2654736A2 (en) 2013-10-30
SI4159204T1 (sl) 2024-06-28
PL2654736T3 (pl) 2020-12-14
AU2011349422A1 (en) 2013-05-02
JP6126014B2 (ja) 2017-05-10
DOP2013000138A (es) 2013-11-30
LT4159205T (lt) 2024-05-10
AU2011349422B2 (en) 2015-12-10
JP2014510704A (ja) 2014-05-01
ZA201304189B (en) 2014-02-26
AR122185A2 (es) 2022-08-24
CY1123376T1 (el) 2021-12-31
NZ612157A (en) 2015-05-29
RS65497B1 (sr) 2024-06-28
MX2013007073A (es) 2013-09-26
FI4159205T3 (fi) 2024-04-23
CL2013001779A1 (es) 2014-06-27
US20140099365A1 (en) 2014-04-10
SI2654736T1 (sl) 2020-10-30
MA34883B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
AR084102A1 (es) Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
AR121359A2 (es) Un comprimido veterinario sólido que se comprime directamente a partir del polvo que no se sometió a una etapa de granulación, que comprende meloxicam o una de sus sales farmacéuticamente aceptables y excipientes
UA116334C2 (uk) Тверді форми дозування бендамустину
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
CR11709A (es) Preparacion solida de desintegracion oral
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
AR065096A1 (es) Preparacion solida
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
ES2574836T3 (es) Formulación de liberación prolongada de nevirapina
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
HRP20180219T1 (hr) Sredstvo za uporabu u slučaju netolerancije na fruktozu
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
BRPI0513598A (pt) formas de dosagem em comprimidos revestidos de liberação entérica
AR097512A1 (es) Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
AR097202A1 (es) Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa
AR080895A1 (es) Formulacion de comprimido de ezatiostat
RU2017126111A (ru) Сложные капсулы, содержащие ралоксифен и витамин D и его производные
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite

Legal Events

Date Code Title Description
FC Refusal